• Regorafenib Suppresses Melanoma Through RRM2

  2026-08-18

  A 2024 iScience study identifies RRM2 as a downstream mediator of Regorafenib activity in melanoma and connects its reduction with impaired proliferation, invasion, metastasis, and increased apoptosis. The work further places the ERK/E2F3 pathway upstream of this response, providing a mechanistic framework for cancer biology research while remaining preclinical.

• Nilotinib Assays: Separating Arrest From Death

  2026-08-18

  Nilotinib (AMN-107) is a powerful probe for BCR-ABL signaling, but kinase potency does not automatically equal cancer-cell killing. This guide applies a phenotype-aware assay framework to chronic myeloid leukemia research, KIT-driven models, and more interpretable viability experiments.

• How Ribotoxic Stress Drives UV-Mediated Cell Death

  2026-08-17

  Sinha et al. show that UV-induced apoptosis is governed primarily by ribosome collisions and the ribotoxic stress kinase ZAK, rather than by the DNA damage response alone. Their time-resolved, multi-method analysis defines GCN2 activation and ZAK degradation as feedback mechanisms that tune cellular tolerance versus death after UV exposure.

• Losmapimod: From p38 Biology to Assay Design

  2026-08-17

  Losmapimod (GW856553X) is a selective p38α/p38β MAPK inhibitor with applications in inflammation, vascular, hypertension, and COPD research. This guide translates new activation-loop biology into practical assay decisions while separating established evidence from testable mechanistic hypotheses.

• U0126-EtOH: MEK1/2 Inhibitor Workflows

  2026-08-16

  U0126-EtOH is a selective MEK1/2 inhibitor for resolving ERK-dependent effects in neuronal, leukemia, and inflammatory models. This practical guide connects pathway validation with dosing, controls, endpoint selection, and troubleshooting for reproducible MAPK/ERK experiments.

• Regorafenib (BAY 73-4506) Assay Guide

  2026-08-15

  A scenario-driven laboratory guide to Regorafenib (BAY 73-4506), SKU A8236, for viability, proliferation, migration, invasion, and angiogenesis research. It connects concentration planning, solvent compatibility, mechanistic interpretation, and product-selection criteria to published melanoma findings and documented kinase activity.

• PPT and the ERα-to-LUAD Translation Gap

  2026-08-14

  PPT (Propyl Pyrazole Triol) offers a pharmacological way to isolate ERα activity from ERβ signaling. By connecting its subtype-selective mechanism with the FOXM1–ERα biomarker network reported in female lung adenocarcinoma, this article outlines a disciplined path from receptor perturbation to translational hypothesis testing.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-08-14

  Chen and colleagues show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through ERK1/2 activation and disruption of bile-acid homeostasis. The study connects estrogenic signaling, altered bile-acid transport and synthesis, and ERK phosphorylation inhibition as experimentally separable features of phytoestrogen-associated hepatotoxicity.

• Trametinib (GSK1120212) Research Workflows

  2026-08-13

  Trametinib (GSK1120212) converts MEK–ERK pathway suppression into a practical workflow for genotype-aware proliferation, cell-cycle, and apoptosis studies. This guide also shows how to extend those assays into a carefully controlled, hypothesis-generating investigation of APEX2-dependent TERT expression.

• AGTR1, ARBs, and Immune Checkpoint Blockade

  2026-08-13

  A 2024 Journal for ImmunoTherapy of Cancer study identifies AGTR1 as a therapeutic vulnerability in collagen-rich, immune-excluded armored and cold tumors. Its data connect angiotensin receptor blockade with reduced cancer-associated fibroblast collagen production, tumor immune remodeling, and improved immune checkpoint blockade responses, while highlighting important limits on clinical interpretation.

• 17-AAG: HSP90 Inhibition as an Assay Strategy

  2026-08-12

  17-AAG (Tanespimycin) is more than a cytotoxic HSP90 inhibitor: it is a mechanistic probe for client-protein dependence, apoptosis, and assay interpretation. This guide connects oncology workflows with new lessons from norovirus–NINJ1 research without overstating cross-domain evidence.

• CX-4945 (Silmitasertib): CK2 Research Guide

  2026-08-12

  CX-4945, also called Silmitasertib, is an ATP-competitive CK2 inhibitor with reported biochemical potency of 1 nM. It provides a research tool for studying CK2-regulated Akt signaling, apoptosis, cell-cycle control, tumor growth, and host-factor biology in viral infection.

• JXY Promotes M1 Polarization in Colitis-Associated CRC

  2026-08-11

  The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1 phenotype through TLR4-associated signaling. Its integrated in vivo, cellular, transcriptional, and pharmacological design supports immune remodeling as a potential mechanism of tumor control, while also highlighting limits on translating macrophage polarization directly to human therapy.

• Rapamycin (Sirolimus): Reliable mTOR Assays

  2026-08-11

  Learn how Rapamycin (Sirolimus), SKU A8167, can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity experiments. This scenario-based guide covers mechanism, dose selection, solvent controls, phenotype interpretation, and practical supplier evaluation.

• DiscoveryProbe™ Metabolism-related Compound Library

  2026-08-10

  The DiscoveryProbe™ Metabolism-related Compound Library provides a defined set of 493 metabolism-focused small molecules for organizing enzyme, pathway, cellular, and ex vivo screening workflows. It is intended for research use with appropriate assay-specific controls, not for diagnosis, clinical treatment, or unvalidated in vivo conclusions.

15768 records 1/1052 page Next 12345 下5页 Last page